Names
Scemblix® AsciminibIndications and usage
Asciminib is indicated for the treatment of adult patients with:
- Newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).
This indication is approved under accelerated approval based on major molecular response rate. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). - Previously treated Ph+ CML in CP.
- Ph+ CML in CP with the T315I mutation.
Side effects needing medical attention
Most common adverse reactions are upper respiratory tract infections, musculoskeletal pain, fatigue, nausea, rash, and diarrhea.